Blocklisting Six Monthly Return
London: Tuesday, 29 December 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) announces the following blocklisting six monthly return:
1. |
Name of applicant:
|
|
Hutchison China MediTech Limited |
2. |
Name of scheme:
|
|
Hutchison China MediTech Limited Share Option Scheme
|
3. |
Period of return:
|
|
From 29 June 2015 to 28 December 2015 |
4. |
Balance under scheme from previous return:
|
|
472,763 ordinary shares of US$1 each
|
5. |
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
|
|
Nil |
6. |
Number of securities issued/allotted under scheme during period: |
|
18,750 ordinary shares of US$1 each |
|
|
|
|
7. |
Balance under scheme not yet issued/allotted at end of the period:
|
|
454,013 ordinary shares of US$1 each |
8. |
Number and class of securities originally listed and the date of admission:
|
|
2,560,606 ordinary shares of US$1 each admitted on 26 June 2007 |
9. |
Total number of securities in issue at the end of the period: |
|
56,533,118 ordinary shares of US$1 each |
|
|
|
|
Name of contact:
|
|
Christian Hogg |
|
Address of contact:
|
|
21/F., Hutchison House, 10 Harcourt Road, Hong Kong
|
|
Telephone number of contact:
|
|
+852 2121 8200 |
Ends
Chi-Med Christian Hogg, CEO |
Telephone: +852 2121 8200
|
|
|
Panmure Gordon (UK) Limited |
Telephone: +44 20 7886 2500 |
Richard Gray Andrew Potts |
|
|
|
Citigate Dewe Rogerson Anthony Carlisle David Dible |
Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919 |
Notes to Editors
Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.